Double immune attack: new cell combo targets tough childhood cancers
NCT ID NCT07211737
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 4 times
Summary
This early-phase study tests a new combination of two different immune cells—NK cells and CAR-T cells—for children and young adults with neuroblastoma or osteosarcoma that has returned or not responded to standard treatments. The NK cells are designed to help the CAR-T cells work better in the tumor environment. The main goals are to find the safest dose and see if the treatment can shrink tumors. About 27 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
- Supercharged immune cells take aim at childhood cancers
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
- Engineered immune cells take aim at childhood cancer